Pharmacist-led Intervention for Disease and Risk Management in Patients with Ischemic Heart Disease

Not Applicable

Completed

• Conditions: Ischemic Heart Disease; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12622000996763
• Lead Sponsor: Dr. Amjad Khan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-15
• Study Completion: 2022-12-31
• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 330

Inclusion Criteria

Patients with confirmed ischemic heart diseases (e.g Myocardial infarction, angina, history of atherosclerosis) who are admitted to and taking follow-up treatment in the Punjab Institute of Cardiology (PIC) hospital will be recruited for the study. Patients with a previous history of coronary heart disease will also be included. Informed consent will be taken from the patients before conducting the study

Exclusion Criteria

Cardiovascular patients other than ischemic heart diseases will be excluded from the study. Patients who have a shorter stay in the hospital, do not have to ability to self-care, cognitively impaired patients, allergic or contraindicated to cardiovascular medicines, have communicable diseases, and could not complete the study due to hepatic or renal insufficiencies and refused to include in the study would be excluded from the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quality of life of ischemic patients will be assessed by study-specific questionnaire[ 6 months post-intervention commenecent];To assess the role of Clinical Pharmacist for primary and secondary prevention of disease with a study-specific questionnaire[ 6 months post-intervention commencement];Prevalence of risk factors assessed using a study-specific questionnaire.[ 6 months post-intervention commencement]

Secondary Outcome Measures

Name	Time	Method
Health Economic benefits such as quality-adjusted life-years (QALYs) will be assessed by calculating patient out-of-pocket costs and study-specific questionnaire[ 6 months post-intervention commencement];Participant response about disease and risk management will be assessed via study specific questionnaire[ 6 months post-intervention commencement]